- Report
- June 2024
- 200 Pages
Global
From €7088EUR$7,950USD£6,152GBP
- Report
- July 2024
- 133 Pages
Global
From €2229EUR$2,500USD£1,934GBP
- Report
- October 2024
- 200 Pages
Global
From €4413EUR$4,949USD£3,829GBP
- Report
- May 2023
- 73 Pages
Global
From €3116EUR$3,495USD£2,704GBP
- Report
- August 2024
- 164 Pages
Global
From €4454EUR$4,995USD£3,865GBP
- Report
- January 2024
- 172 Pages
Global
From €1953EUR$2,190USD£1,695GBP
- Report
- January 2024
- 110 Pages
Global
From €3500EUR$4,205USD£3,144GBP
- Report
- May 2023
- 78 Pages
Global
From €3500EUR$4,205USD£3,144GBP
- Report
- June 2022
- 99 Pages
Global
From €3500EUR$4,205USD£3,144GBP
- Report
- March 2024
- 132 Pages
Global
From €847EUR$950USD£735GBP
- Report
- March 2024
- 132 Pages
Global
From €847EUR$950USD£735GBP
The Narcolepsy Drug market is a subset of the Central Nervous System Drugs market. Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and sudden, uncontrollable episodes of sleep. Narcolepsy drugs are used to reduce the symptoms of the disorder, such as excessive daytime sleepiness, cataplexy, and sleep paralysis. These drugs are typically stimulants, such as modafinil, armodafinil, and methylphenidate. Other drugs used to treat narcolepsy include tricyclic antidepressants, sodium oxybate, and clonidine.
Some companies in the Narcolepsy Drug market include Cephalon, Inc., Teva Pharmaceuticals, Mylan Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more